Development asset linked to LEO Pharma US in public FDA and regional records.
pharma · Psoriasis Vulgaris · Moderate-to-severe plaque psoriasis and a body weight ≥120 kg.
LEO Pharma US
LEO Pharma A/S
LEO Pharma US drug portfolio — 11 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Madison, USA HQ
1908 Founded
75 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Madison, USA
- Founded
- 1908
- Employees
- 75
- Programs
- 7
- Drugs
- 11
- Patents
- 0
LEO Pharma US pipeline
Portfolio lens on 11 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
LEO Pharma US drug portfolio — 11 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
brodalumab
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Interleukin-17 receptor A.
- Target
- Interleukin-17 receptor A
- Mechanism
- Interleukin-17 receptor A antagonist
-
delgocitinib
Dermatologicals (D11)US regulatory status: approved. Molecular target: Janus Kinase (JAK).
- Target
- Janus Kinase (JAK)
- Mechanism
- Janus Kinase (JAK) inhibitor
-
Development asset linked to LEO Pharma US in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M1.
- Target
- Muscarinic acetylcholine receptor M1
- Mechanism
- Muscarinic acetylcholine receptor M1 antagonist
-
Development asset linked to LEO Pharma US in public FDA and regional records.
-
Development asset linked to LEO Pharma US in public FDA and regional records.
-
Development asset linked to LEO Pharma US in public FDA and regional records.
-
tralokinumab
Dermatologicals (D11)US regulatory status: approved. Molecular target: Interleukin-13.
- Target
- Interleukin-13
- Mechanism
- Interleukin-13 inhibitor
-
Development asset linked to LEO Pharma US in public FDA and regional records.